Symbol

    loading  Checking for direct PDF access through Ovid

Abstract

BACKGROUND:

The relapse rate of patients with high risk acute myelocytic leukemia is very high after treated with autologous hematopoietic stem cells transplantation (AHSCT). How to decrease the relapse rate is still difficult.

OBJECTIVE:

To investigate the clinical efficacy of AHSCT combined with allogenentic cytokine-induced killer cells (CIK cells) and interleukin-2 (IL-2) infusion for treatment of high risk acute myelocytic leukemia (AML).

METHODS:

Two patients with high risk AML were treated with AHSCT at complete remission first time (CR1) after induction and consolidation chemotherapy. One month after AHSCT, two patients were infused with allogenetic CIK cells for 3-4 courses, with one course for half a year, 5 times per course and once per day. Subcutaneous injection with IL-2 was finished at half an hour before infusing CIK cells every time, the subcutaneous injection of IL-2 was preformed once every 2 days after the first infusion and once every 3 days after half a year, once every 4 days after one year, and once a week after one and half a year. The injection was maintained for half a year to prevent the relapse of AML.

RESULTS AND CONCLUSION:

After the two patients were treated with allogenentic CIK cells infusion and subcutaneous injection of IL-2 after AHSCT, there were no side effects appeared such as fever, shivering and erythra, at the same time there were no bone marrow depression and graft versus host disease appeared. The sustained remission time of the two patients was 20 months and 2 years respectively without relapse after AHSCT until now. The first time we find that the patients with high risk AML can acquire disease-free survival longtime with the treatment of AHSCT in combination with immunotherapy of CIK cells and IL-2 when they have no suitable donors.

RESULTS AND CONCLUSION:

Tu SF, Song CY, Li YH, Guo KY, Huang YX. Autologous hematopoietic stem cell transplantation in combination with allogenetic cytokine induced killer cells and interleukin-2 infusion for treatment of high risk acute myelocytic leukemia in two cases.Zhongguo Zuzhi Gongcheng Yanjiu. 2012;16(10): 1897-1900. [http://www.crter.cnhttp://en.zglckf.com]

Related Topics

    loading  Loading Related Articles